AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16816226 — intervention group
Group type: COMPARATOR
Intervention: Control condition (28 families, 130 individuals)
Number of subjects: 81
Study 12508190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT)
Number of subjects: 18
Study 11434951 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention in KNOOP-3 trial
Number of subjects: 0
Study 11434951 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention in TARGET trial
Number of subjects: 0
Study 11434951 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised eligible patients
Number of subjects: 0
Study 9219391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine as an adjunct to treatment for cocaine abuse
Number of subjects: 0
Study 9219391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7962503 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotomized fibula
Number of subjects: 35
Study 7962503 — intervention group
Group type: COMPARATOR
Intervention: Intact fibula
Number of subjects: 35
Study 7962503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 3591689 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine therapy at incremental doses of 2.5, 5, 7.5, 10, 12.5 and 15 micrograms/kg/min
Number of subjects: 79
Study 3591689 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone as a bolus of 50 or 75 micrograms/kg followed by an infusion of 0.5 to 1.0 micrograms/kg/min
Number of subjects: 79
Study 3591689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both milrinone and dobutamine
Number of subjects: 79
Study 3591689 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 79
Study 3591689 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 79
Study 29161767 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIT)
Number of subjects: 45
Study 29161767 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 45
Study 29161767 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 45
Study 27142057 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE intervention (multi-component, school-based HIV prevention intervention)
Number of subjects: 6244
Study 27142057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6244
Study 25767373 — intervention group
Group type: EXPERIMENTAL
Intervention: Revexepride 1 mg
Number of subjects: 42
Study 25767373 — intervention group
Group type: COMPARATOR
Intervention: Revexepride 1 mg + Omeprazole 40 mg
Number of subjects: 42
Study 23620327 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic fetal biometry
Number of subjects: 200
Study 23620327 — intervention group
Group type: COMPARATOR
Intervention: Manual fetal biometry
Number of subjects: 200
Study 21741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-induced reactivity in relapsers
Number of subjects: 31
Study 21741031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-induced cortisol response
Number of subjects: 31
Study 21741031 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 19917849 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care program by a nurse
Number of subjects: 164
Study 19917849 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 164
Study 16491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective anterior resection of the rectum
Number of subjects: 6833
Study 16491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical anastomotic leakage
Number of subjects: 6833
Study 16491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 6833
Study 16491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 6833
Study 16491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' 'D' stage
Number of subjects: 6833
Study 16491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative adverse events
Number of subjects: 6833
Study 14695468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 20
Study 14695468 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 11059568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 67
Study 11059568 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study 9282236 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (TH) with 0.5 mg terbutaline
Number of subjects: 118
Study 9282236 — intervention group
Group type: EXPERIMENTAL
Intervention: pressurized metered-dose inhaler (pMDI) with 0.5 mg terbutaline
Number of subjects: 118
Study 9282236 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (TH)
Number of subjects: 118
Study 9282236 — intervention group
Group type: COMPARATOR
Intervention: pressurized metered-dose inhaler (pMDI)
Number of subjects: 118
Study 8334346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheng Mai injection
Number of subjects: 30
Study 8334346 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 30
Study 3113147 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration (8 mg iv as a bolus followed by an infusion of 4 mg/h for 4 h)
Number of subjects: 10
Study 3113147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 10
Study 3113147 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg im every two weeks)
Number of subjects: 10
Study 3113147 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 10
Study 31736457 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempt
Number of subjects: 1326
Study 29921624 — intervention group
Group type: EXPERIMENTAL
Intervention: Penn Resilience Program for type 1 diabetes (PRP T1D)
Number of subjects: 264
Study 29921624 — intervention group
Group type: COMPARATOR
Intervention: Advanced Diabetes Education
Number of subjects: 264
Study 26526702 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 14180
Study 26526702 — intervention group
Group type: COMPARATOR
Intervention: No arterial hypertension
Number of subjects: 14180
Study 25551811 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with 0.5ml (2.5µg) sufentanil added to 1ml hyperbaric bupivacaine (Group BS)
Number of subjects: 62
Study 25551811 — intervention group
Group type: COMPARATOR
Intervention: Unilateral spinal anaesthesia with 1ml 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 62
Study 22032285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (2 L/min through nasal prongs)
Number of subjects: 10
Study 22032285 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 10
Study 22032285 — intervention group
Group type: EXPERIMENTAL
Intervention: Either oxygen or ASV
Number of subjects: 10
Study 22032285 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 10
Study 22032285 — intervention group
Group type: COMPARATOR
Intervention: ASV
Number of subjects: 10
Study 22032285 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy and ASV
Number of subjects: 10
Study 21170109 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Gel 5.0 g
Number of subjects: 96
Study 21170109 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Gel 7.5 g
Number of subjects: 96
Study 21170109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17971716 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count-guided episodic antiretroviral therapy
Number of subjects: 1225
Study 17971716 — intervention group
Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 1225
Study 21596364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) added to stable rosuvastatin 5 mg or 10 mg
Number of subjects: 440
Study 21596364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus rosuvastatin 5 mg
Number of subjects: 440
Study 21596364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus rosuvastatin 10 mg
Number of subjects: 440
Study 21596364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) added to stable rosuvastatin
Number of subjects: 440
Study 21596364 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin up-titration
Number of subjects: 440
Study 16275885 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil twice daily for 4 weeks
Number of subjects: 16
Study 16275885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11865971 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg Cenestin (Synthetic Conjugated Estrogens, A) tablets, administered once daily for 90 days
Number of subjects: 15
Study 9658709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 0
Study 9658709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 9658709 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 7650466 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine breast screening (mammography)
Number of subjects: 1500
Study 7650466 — intervention group
Group type: EXPERIMENTAL
Intervention: Women receiving false positive results
Number of subjects: 1500
Study 7650466 — intervention group
Group type: COMPARATOR
Intervention: Non-attenders
Number of subjects: 1500
Study 2505269 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (150 mg)
Number of subjects: 202
Study 2505269 — intervention group
Group type: COMPARATOR
Intervention: ADM (50 mg)
Number of subjects: 202
Study 2505269 — intervention group
Group type: COMPARATOR
Intervention: TTPA (50 mg)
Number of subjects: 202
Study 800384 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 57
Study 800384 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 57
Study 800384 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations
Number of subjects: 57
Study 11514481 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for secondary prevention of coronary heart disease (CHD)
Number of subjects: 3963
Study 11514481 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 30% over 10 years
Number of subjects: 3963
Study 11514481 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 20% over 10 years
Number of subjects: 3963
Study 11514481 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 15% over 10 years
Number of subjects: 3963
Study 11514481 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention at CHD risk 6% over 10 years
Number of subjects: 3963
Study 11514481 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment at projected CHD risk 20% over 10 years
Number of subjects: 3963
Study 30873671 — intervention group
Group type: EXPERIMENTAL
Intervention: Black seed capsules (500 mg) two times per day for 10 weeks
Number of subjects: 60
Study 30873671 — intervention group
Group type: COMPARATOR
Intervention: Placebo two times per day for 10 weeks
Number of subjects: 60
Study 28539071 — intervention group
Group type: EXPERIMENTAL
Intervention: FlashWord intervention (n = 9)
Number of subjects: 15
Study 28539071 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention (n = 6)
Number of subjects: 15
Study 27378000 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dexketoprofen trometamol (25 mg 30 min before surgery)
Number of subjects: 60
Study 27378000 — intervention group
Group type: COMPARATOR
Intervention: Postoperative dexketoprofen trometamol (25 mg immediately after surgery)
Number of subjects: 60
Study 27378000 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dexketoprofen trometamol
Number of subjects: 60
Study 27378000 — intervention group
Group type: COMPARATOR
Intervention: Postoperative dexketoprofen trometamol
Number of subjects: 60
Study 24813652 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (brief advice and input from an AHW)
Number of subjects: 802
Study 24813652 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 802
Study 24813652 — intervention group
Group type: COMPARATOR
Intervention: Control (leaflet providing general information on health and lifestyle)
Number of subjects: 802
Study 24813652 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 802
Study 22122062 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 50
Study 22122062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no KMC)
Number of subjects: 50
Study 20199786 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/d)
Number of subjects: 50
Study 20199786 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg/d)
Number of subjects: 50
Study 20199786 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with Ezetimibe
Number of subjects: 50
Study 20199786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Simvastatin + Ezetimibe)
Number of subjects: 50
Study 17609306 — intervention group
Group type: EXPERIMENTAL
Intervention: 1850 MBq (131)I after rhTSH
Number of subjects: 72
Study 17609306 — intervention group
Group type: COMPARATOR
Intervention: 3700 MBq (131)I after rhTSH
Number of subjects: 72
Study 15889952 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quetiapine (493 mg/day at week 48)
Number of subjects: 35
Study 15889952 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol decanoate (170 mg/28 days at week 48)
Number of subjects: 35
Study 15889952 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quetiapine
Number of subjects: 35
Study 15889952 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol decanoate
Number of subjects: 35
Study 12562481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral vertical infraclavicular brachial plexus (LVIBP) block
Number of subjects: 40
Study 12562481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral vertical infraclavicular brachus plexus (LVIBP) block
Number of subjects: 40
Study 12562481 — intervention group
Group type: COMPARATOR
Intervention: Axillary brachial plexus (ABP) block
Number of subjects: 40
Study 10496715 — intervention group
Group type: EXPERIMENTAL
Intervention: Levovist-enhanced ultrasound
Number of subjects: 18
Study 10496715 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced ultrasound
Number of subjects: 18
Study 8671571 — intervention group
Group type: EXPERIMENTAL
Intervention: High titre measles vaccine
Number of subjects: 0
Study 8671571 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium titre measles vaccine
Number of subjects: 0
Study 8671571 — intervention group
Group type: EXPERIMENTAL
Intervention: High titre measles vaccine (females)
Number of subjects: 0
Study 8671571 — intervention group
Group type: EXPERIMENTAL
Intervention: High titre measles vaccine (males)
Number of subjects: 0
Study 8671571 — intervention group
Group type: COMPARATOR
Intervention: Standard titre measles vaccine
Number of subjects: 0
Study 1931060 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 50
Study 1931060 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium (1.0 mg/kg to 4 mg/kg)
Number of subjects: 50
Study 6210665 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (1.5 g) administered intramuscularly every 6 hr for seven to ten days
Number of subjects: 60
Study 6210665 — intervention group
Group type: COMPARATOR
Intervention: ticarcillin (2 g) administered intramuscularly every 6 hr for seven to ten days
Number of subjects: 60
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal incision with a 2.20 mm keratome
Number of subjects: 100
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal incision with a 2.85 mm keratome
Number of subjects: 100
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative corneal first applanation stiffness parameter
Number of subjects: 100
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative first applanation velocity
Number of subjects: 100
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative second applanation velocity
Number of subjects: 100
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative first applanation deformation amplitude
Number of subjects: 100
Study 30474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative deflection amplitude at highest concavity
Number of subjects: 100
Study 30672213 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture at Zusanli (ST 36) and Guanyuan (CV 4) combined with ginger moxibustion at Baliao points, 30 min a time, once a day, 5 times a week for 3 courses (1 month each).
Number of subjects: 50
Study 30672213 — intervention group
Group type: COMPARATOR
Intervention: Climen tablet prescribed orally from the 5th day of menstruation, one tablet a time, once a day for 3 months (7 days between two 21-day medication).
Number of subjects: 50
Study 27107779 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sessions of accelerated intermittent Theta-burst Stimulation (iTBS) applied to the left dorsolateral prefrontal cortex (DLPFC) over four days
Number of subjects: 50
Study 27107779 — intervention group
Group type: COMPARATOR
Intervention: Sham-controlled iTBS protocol
Number of subjects: 50
Study 24604606 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Rayner 920H)
Number of subjects: 30
Study 24604606 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL (Rayner 620H)
Number of subjects: 30
Study 22305715 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic mineralization system (BIMIN)
Number of subjects: 40
Study 22305715 — intervention group
Group type: COMPARATOR
Intervention: Gluma(®) Desensitizer
Number of subjects: 40
Study 20667889 — intervention group
Group type: EXPERIMENTAL
Intervention: posaconazole 400 mg twice daily
Number of subjects: 24
Study 20667889 — intervention group
Group type: COMPARATOR
Intervention: fosamprenavir/ritonavir 700/100 mg twice daily
Number of subjects: 24
Study 20667889 — intervention group
Group type: EXPERIMENTAL
Intervention: posaconazole 400 mg twice daily with fosamprenavir 700 mg twice daily
Number of subjects: 24
Study 17125876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b and ribavirin for 24 weeks
Number of subjects: 129
Study 17125876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b and ribavirin
Number of subjects: 129
Study 17125876 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 17125876 — intervention group
Group type: EXPERIMENTAL
Intervention: SVR patients
Number of subjects: 129
Study 16376207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelastic compression garment (CircAid)
Number of subjects: 12
Study 16376207 — intervention group
Group type: COMPARATOR
Intervention: Four-layer elastic bandage
Number of subjects: 12
Study 11973215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% plus fentanyl 2 microg/mL
Number of subjects: 60
Study 11973215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% plus fentanyl 2 microg/mL
Number of subjects: 60
Study 11973215 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 9454395 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of penicillin
Number of subjects: 599
Study 9454395 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin tablets for six days
Number of subjects: 599
Study 9454395 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 599
Study 9454395 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and C
Number of subjects: 599
Study 9454395 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group B and C
Number of subjects: 599
Study 8585875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy at a dose of 20 mg/die
Number of subjects: 23
Study 8585875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8585875 — intervention group
Group type: COMPARATOR
Intervention: Dietetic treatment and placebo after pravastatin suspension
Number of subjects: 23
Study 2613719 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mechanical conditioning followed by non‐destructive repeated testing to 0.6% strain and a final destructive test
Number of subjects: 121
Study 2613719 — intervention group
Group type: COMPARATOR
Intervention: Destructive axial compression test‐series
Number of subjects: 121
Study 356764 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen suppositories
Number of subjects: 35
Study 356764 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories
Number of subjects: 35
Study 356764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31832851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 60
Study 31832851 — intervention group
Group type: COMPARATOR
Intervention: Baseline NK cell proportions
Number of subjects: 60
Study 31104477 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Leprosy framework with SMS reminders
Number of subjects: 188
Study 27640940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension on transcervical balloon catheter
Number of subjects: 140
Study 27640940 — intervention group
Group type: COMPARATOR
Intervention: No tension on transcervical balloon catheter
Number of subjects: 140
Study 25035081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 48
Study 25035081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23313720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program (n = 54)
Number of subjects: 106
Study 23313720 — intervention group
Group type: COMPARATOR
Intervention: Attention and dose‐matched control program (n = 52)
Number of subjects: 106